β-1,4 Galactan Adjuvant Composition for TAM Reprogramming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing immunomodulators for tumor microenvironment remodeling in cancer immunotherapy suffer from non-specific immune activity, low solubility, and biocompatibility issues, and high costs, limiting their effectiveness in enhancing immune response in tumors with low immune reactivity.
Innovation Solution
A galactose polymer (Gal-NC) interconnected by β-1,4 bonds, derived from pectin heteropolysaccharides, is used to re-educate tumor-associated macrophages, promoting TLR4-specific activation and repolarization into M1-like phenotype, enhancing anti-tumor immunity when combined with immunotherapy drugs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule stimulants are used for immune activation, then immune response is enhanced, but non-target effects and low biocompatibility occur
Solution Approach 1:
The patent changes the chemical structure from small molecules to complex carbohydrate polymers with specific molecular weights (10,000-1,000,000 Da) and defined glycan residues, transforming the interaction mechanism to achieve selective immune activation through pattern recognition receptors while improving biocompatibility
Solution Approach 2:
The invention uses composite carbohydrate structures combining multiple glycan residues (galactan, arabinan, xyloglucan) with specific linkage patterns to create a multifunctional adjuvant that simultaneously activates immune responses and maintains biocompatibility through natural carbohydrate chemistry
2Reliability
If bacterial lipid structure immunostimulants are used, then immune activity is enhanced, but non-specific immune activity and low solubility occur
Solution Approach 1:
The patent transitions from bacterial lipid structures to plant-derived carbohydrate polymers with specific molecular weight ranges and glycan compositions, changing the chemical parameters to achieve specific immune activation through TLR recognition while improving water solubility and reducing non-specific effects
Solution Approach 2:
The invention copies the successful immune activation mechanism of bacterial lipids by creating synthetic carbohydrate structures that mimic pathogen-associated molecular patterns (PAMPs), allowing TLR4 and other pattern recognition receptors to recognize and activate immune responses without using actual bacterial components
3Object-affected harmful factors
If proteins, cytokines, and antibodies are used for immune modulation, then biocompatibility is improved, but stability and cost deteriorate
Solution Approach 1:
The patent uses inexpensive plant-derived carbohydrate polymers that are chemically stable and can be produced at scale, replacing expensive proteins and antibodies while maintaining biocompatibility through the use of natural sugar monomers that are renewable and cost-effective to manufacture
Solution Approach 2:
The invention changes the molecular parameters from macromolecular proteins to polysaccharide polymers with controlled molecular weights and glycan compositions, improving chemical stability through carbon-carbon backbone structures while maintaining biocompatibility through natural carbohydrate chemistry
4Productivity
If existing immunotherapy is used in tumors with low immune response, then treatment is administered, but efficacy is insufficient
Solution Approach 1:
The patent applies preliminary immunological stimulation using carbohydrate adjuvants before or concurrent with immunotherapy administration, pre-activating pattern recognition receptors and shaping the immune response to enhance subsequent anti-cancer efficacy in tumors with low immune responsiveness
Solution Approach 2:
The invention uses carbohydrate polymers as intermediary molecules that bridge the gap between tumor antigens and the immune system, activating pattern recognition receptors to amplify and optimize the immune response to cancer cells, thereby improving efficacy in immune-hyporesponsive tumors
Data Source
AI summary
The present invention relates to an adjuvant composition including a galactose polymer which is interconnected by β-1,4 bonds. The adjuvant composition of the present invention is a novel immunoactive adjuvant including an immunoactive structure having a galactan repeating sugar structure that has not been previously identified, and it has different mechanisms of action and operating principles compared to existing adjuvants. The adjuvant composition of the present invention has a structure based on plant natural polysaccharides, and it has high economic feasibility due to the characteristics of the carbohydrate structure, is biodegradable and thus environmentally friendly, and has high chemical stability. In addition, the adjuvant composition of the present invention has the advantage of increasing anti-cancer efficacy when used in combination with existing immunotherapy drugs as an immune checkpoint inhibitor by activating tumor-associated macrophages in a tumor microenvironment, and particularly has the advantage of excellent efficacy on tumors with low immune response.